FRIDAY, June 27, 2025 (HealthDay News) -- Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among ...

In adults with type 2 diabetes who had not previously received insulin, once-weekly efsitora, administered in a fixed-dose regimen, was noninferior to once-daily glargine in reducing glycated ...

US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials ...

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...

Lantus – said to be the most administered basal insulin across the world – continues to make blockbuster sales, bringing in almost $775 million for Sanofi in the first quarter of this year.

An experimental once-weekly insulin known as efsitora has shown comparable effectiveness to daily insulin regimens in managing blood sugar levels among adults with type 2 diabetes, according to ...

In QWINT-3, the respective rates were 0.84 for efsitora and 0.74 for insulin degludec at 78 weeks. In QWINT-4, the rates were 6.6 for efsitora and 5.9 for insulin glargine at 26 weeks.

compared with once-daily insulin glargine U100 (8.28% to 7.08%) over 52 weeks in insulin-naïve adults with type 2 diabetes (the estimated between-group difference of -0.03 percentage points, 95% CI -0 ...

Biocon Biologics Ltd. (BBL) on Monday announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the supply of ...

Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.